ArticlePediatric nephrology (Berlin, Germany)2026
Incidence and risk factors of vancomycin-associated nephrotoxicity among neonates in the intensive care unit: a retrospective cohort study.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVancomycin-induced nephrotoxicity is associated with an increased risk of neonatal mortality and prolonged neonatal intensive care unit (NICU) stay. This retrospective cohort study aimed to assess the incidence of vancomycin-associated nephrotoxicity and its risk factors in neonates.
methodsThe study included neonates admitted to the NICU of the Maternity and Children Hospital (Makkah, Saudi Arabia) from January 2018 to December 2020 who received intravenous vancomycin for more than 48 h. The primary outcome was the incidence of newly developed acute kidney injury (AKI) after the initiation of vancomycin therapy, defined according to the neonatal modified Kidney Disease: Improving Global Outcomes criteria. Analyses included AKI incidence, comparison of clinical parameters between neonates with and without AKI, and multivariable logistic regression to identify predictors of AKI and mortality.
resultsAmong 362 neonates treated with vancomycin, 11.3% developed AKI. Neonates with AKI had a lower postmenstrual age (31.3 vs. 34.1 weeks, p = 0.01) and higher rates of extreme prematurity (31.7% vs. 14.3%, p = 0.02) and extremely low birth weight (43.9% vs. 18.7%, p = 0.00). Vancomycin trough levels > 15 mg/L were more frequent in the AKI group (26.8%, 11/41) than in others (11.8%, 35/321) (p = 0.00). Only one-third of vancomycin trough measurements were obtained according to guideline-recommended timing. In multivariable analysis, each additional week of postmenstrual age was independently associated with a 10% reduction in the odds of AKI (OR 0.90; p = 0.00). Higher weight was associated with lower mortality (OR = 0.26; p < 0.001), while AKI incidence was associated with increased mortality (OR = 5.88; p < 0.001). Caffeine citrate use was associated with lower odds of mortality, but was not associated with AKI (OR = 0.21; p < 0.001).
conclusionLower postmenstrual age independently predicted vancomycin-associated AKI. Lower neonatal weight and AKI were associated with increased mortality, reinforcing the importance of individualized monitoring during vancomycin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.